Angiotensin II–Stimulating Antihypertensive Medications and Dementia-Related Neuropathology
JAMA Network Open · 11.02.2026 · 9 (2) · e2559113
DOI: 10.1001/jamanetworkopen.2025.59113 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 11.02.2026. Verfasst von Shelly L Gray und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, School of Pharmacy, University of Washington, Seattle. Hauptthemen laut MEDLINE: Antihypertensive Agents, Angiotensin II, Dementia, Hypertension. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
Importance Antihypertensive medications that stimulate angiotensin II type 2 or 4 receptors (angiotensin II–stimulating medications) may be associated with lower risk of dementia.
Objective
To examine associations between cumulative exposure to angiotensin II–stimulating vs angiotensin II–inhibiting antihypertensive medications and neuropathology, accounting for blood pressure. Design, Setting, and Participants This community-based autopsy cohort study from the Adult Changes in Thought cohort was conducted at Kaiser Permanente Washington between February 24, 1994, and November 25, 2022, among 756 participants who had blood pressure measurements and at least 1 person-year (PY) of angiotensin II–stimulating or –inhibiting antihypertensive medication exposure prior to death. Statistical analysis was performed between September 2024 and August 2025. Exposure Angiotensin II–stimulating antihypertensive medications (angiotensin II receptor blockers, dihydropyridine calcium channel blockers, thiazides) and angiotensin II–inhibiting antihypertensive medications (angiotensin-converting enzyme inhibitors, β-blockers, nondihydropyridine calcium channel blockers) were ascertained from paper-based medical records (before 1977) and electronic prescription fill data (after 1977). The primary exposure was cumulative angiotensin II PYs, and the secondary exposure was long-term use (≥15 years). Main Outcomes and Measures Neuropathology outcomes were classified as Alzheimer disease related, vascular brain injury, or other. Exploratory outcomes included quantitative measures of Aβ42 and phosphorylated tau. Data were analyzed using multivariable modified Poisson, proportional odds, and linear regression models and accounted for potential selection bias.
Results
The sample included 756 participants (mean [SD] age at death, 89.2 [6.4] years; 440 women [58.2%]; mean [SD] follow-up, 22.2 [13.5] years). Compared with exposure to 5 additional PYs of angiotensin II–inhibiting antihypertensive medications, exposure to 5 additional PYs of angiotensin II–stimulating antihypertensive medications was associated with a 6% lower risk for arteriolosclerosis (relative risk [RR], 0.94; 95% CI, 0.89-0.99), with long-term use associated with a 24% lower risk (RR, 0.76; 95% CI, 0.63-0.91). For exploratory outcomes, PYs of angiotensin II–stimulating antihypertensive medications were associated with less quantitative phosphorylated tau burden in several brain regions (temporal lobe [adjusted ratio of geometric means, 0.79; 95% CI, 0.62-1.00], hippocampus [adjusted ratio of geometric means, 0.83; 95% CI, 0.71-0.97], cornu ammonis subfield 1 [adjusted ratio of geometric means, 0.86; 95% CI, 0.74-0.99], and transentorhinal cortex [adjusted ratio of geometric means, 0.83; 95% CI, 0.70-0.98]) but not with Aβ42 quantitative measures. Conclusions and Relevance In this community-based autopsy cohort study, angiotensin II–stimulating antihypertensive medications were associated with lower risk of neuropathological burden, supporting findings from epidemiologic dementia studies. Additional mechanistic research examining the effects of individual antihypertensive classes on Alzheimer disease–related biomarkers is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, School of Pharmacy, University of Washington, Seattle.
- Kaiser Permanente Washington Health Research Institute, Seattle, Washington.
- Department of Laboratory Medicine and Pathology, University of Washington, Seattle.
- Department of Public and Occupational Health, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
- Department of Neurology, Donders Institute for Brain, Behaviour and Cognition, Radboud University Medical Centre, Nijmegen, the Netherlands.
- School of Medicine, University of Washington, Seattle.
Förderung
- NIA NIH HHS
Zitieren
APA
Gray, S. L., Yu, O., Gatto, N. M., Marcum, Z. A., Latimer, C. S., Postupna, N., Su, Y. R., Barthold, D., van Dalen, J. W., Richard, E., Keene, C. D., Shaw, P. A., McEvoy, L. K., Larson, E. B., & Crane, P. K. (2026). Angiotensin II–Stimulating Antihypertensive Medications and Dementia-Related Neuropathology. JAMA Network Open, 9(2), e2559113. https://doi.org/10.1001/jamanetworkopen.2025.59113
Vancouver
Gray SL, Yu O, Gatto NM, Marcum ZA, Latimer CS, Postupna N, et al. Angiotensin II–Stimulating Antihypertensive Medications and Dementia-Related Neuropathology. JAMA Network Open. 2026;9(2):e2559113. doi:10.1001/jamanetworkopen.2025.59113
BibTeX
@article{Gray2026,
author = {Gray, Shelly L and Yu, Onchee and Gatto, Nicole M and Marcum, Zachary A and Latimer, Caitlin S and Postupna, Nadia and Su, Yu-Ru and Barthold, Douglas and van Dalen, Jan Willem and Richard, Edo and Keene, C Dirk and Shaw, Pamela A and McEvoy, Linda K and Larson, Eric B and Crane, Paul K},
title = {Angiotensin II–Stimulating Antihypertensive Medications and Dementia-Related Neuropathology},
journal = {JAMA Network Open},
year = {2026},
volume = {9},
number = {2},
pages = {e2559113},
doi = {10.1001/jamanetworkopen.2025.59113}
}
EUVIMED